menu

Cardiovascular Risk Reduction for Adults With Type 2 Diabetes & ASCVD: A Collaborative Approach

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Cardiovascular Risk Reduction for Adults With Type 2 Diabetes & ASCVD: A Collaborative Approach

Program Information
Recommended

Program Information

ReachMD Healthcare Image
RestartResume

How can we optimize our multidisciplinary approach to help reduce cardiovascular risk in patients with type 2 diabetes and cardiovascular disease?

  • Sponsored by

  • Overview

    Patients with type 2 diabetes may have a number of comorbidities like atherosclerotic cardiovascular disease (ASCVD) that can complicate their treatment plan. These comorbidities could require not only endocrinologists, but also cardiologists, nephrologists, and primary care physicians to address all aspects of the disease. That’s why Drs. Matthew Budoff and Joshua Stolker join Dr. Charles Turck to share their perspectives on collaborative care strategies to help improve patient care and to enhance our own approach to managing patients with type 2 diabetes and ASCVD.

    Novo Nordisk is a registered trademark of Novo Nordisk A/S.
    © 2022 Novo Nordisk All rights reserved.
    US22DI00251 September 2022

Schedule7 Dec 2022